Capricor Therapeutics Inc (CAPR) is a publicly traded Healthcare sector company. As of May 21, 2026, CAPR trades at $29.01 with a market cap of $1.62B and a P/E ratio of -24.46. CAPR moved +7.82% today. Year to date, CAPR is +16.93%; over the trailing twelve months it is +163.49%. Its 52-week range spans $4.30 to $40.37. Analyst consensus is strong buy with an average price target of $54.50. Rallies surfaces CAPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Capricor Therapeutics Eyes 27.47% Upside and FDA Decision by August 22: Roth Capital set a $38 price target on Capricor Therapeutics, implying a 27.47% upside from its $29.81 stock price as its Duchenne therapy deramiocel nears the FDA’s August 22, 2026 PDUFA decision. Capricor holds $279 million cash to fund independent commercialization despite its NS Pharma legal dispute.
| Metric | Value |
|---|---|
| Price | $29.01 |
| Market Cap | $1.62B |
| P/E Ratio | -24.46 |
| EPS | $-1.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.37 |
| 52-Week Low | $4.30 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $22.27M |
| Net Income | $-40.47M |
| Gross Margin | 0.00% |
8 analysts cover CAPR: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.50.